Talk:Lenacapavir

Want: pharmacokinetics
This drug has just made the news from a twice-yearly trial. It probably has some really interesting pharmacokinetics; https://liverpool-hiv-hep.s3.amazonaws.com/prescribing_resources/pdfs/000/000/229/original/HIV_FactSheet_LEN_2022_Oct.pdf?1665666788 (a summary of the official Summary of Product Characteristics — cite the official thing!) does show some long half-lives. —Artoria2e5 🌉 05:54, 21 June 2024 (UTC)

Also poorly soluble in water so given as a PEG suspension. Wait, did it say picomolar? (https://pubmed.ncbi.nlm.nih.gov/37917742/) —Artoria2e5 🌉 05:56, 21 June 2024 (UTC)


 * I wanted to update the page to reflect the recent impressive efficacy data, but all media sources seem to reference Gilead's press release. Is it best to wait until there's a more detailed press release ("More detailed data from PURPOSE 1 will be presented at a future conference.") and/or an official record of the end of the blinded phase of the trial? RFZYN SPY  talk 19:22, 21 June 2024 (UTC)
 * It could be. Let’s at least wait for a preprint on that. Artoria2e5 🌉 07:25, 22 June 2024 (UTC)